Contact

Please select a country

us@pharmalex.com

Contact United States

TwitterLinkedin
contact@pharmalex.com
  • News & Events
    • News
    • Webinars
    • Events
Top Bar
Search
PharmaLexPharmaLex
PharmaLex
Confidence Beyond Compliance
  • About Us
    • About Us
    • Management Team
    • Industry Expertise
      • Biopharma
      • Customer On-site Support
      • Portfolio Maintenance Outsourcing
      • Medical Device Services
    • What Our Clients Say About Us
    • Our Approach
    • Resource Library
  • Our Services
    • Choose a Service
    • InnoPHLEX
    • SourcePHLEX
    • SmartPHLEX
    • Development Consulting
    • Regulatory Affairs
    • Quality Management & Compliance
    • Pharmacovigilance, Epidemiology & Risk Management
    • Medical Device Services
    • Brexit
  • Countries
  • Contact us
  • Careers
    • Current Opportunities
    • Why work at PharmaLex
    • Working at PharmaLex
  • Training
Menu back  
Home > News & Events > Ireland > New Annex 1 – Consequences for the QP

New Annex 1 – Consequences for the QP

New Annex 1

The highly anticipated draft of Eudralex Volume 4 Annex 1 “Manufacture of Sterile Medicinal Products” was released on the 20th December 2017 and since this date the pharmaceutical industry has compiled and communicated significant feedback on the wording and content of the augmented and enlarged document. Potential wording changes notwithstanding, it is anticipated that the general intention of the new draft will remain intact. The significant number of clarifications and additions to the guidelines brings consequences for all QPs currently involved in batch disposition of sterile products. One of the major changes contained in the new document is the reference to the Contamination Control Strategy and its function which was first introduced in the updates to Eudralex Volume 4 Part 1 Chapter 3 and Chapter 5 in 2015. The new Annex 1 states “A contamination control strategy should be implemented across the facility in order to assess the effectiveness of all the control and monitoring measures employed. This assessment should lead to corrective and preventative actions being taken as necessary” and further states that “Sole reliance for sterility or other quality aspects must not be placed on any terminal process or finished product test.” The intention of these statements is to initiate a move away from reliance on finished product tests such as sterility testing as a marker of overall batch sterility and a move towards prospective sterility assurance and contamination control which is firmly rooted in QRM principles with all relevant elements brought together holistically in one overall strategy of control and monitoring. This intention is further emphasised in the document where it is states that a “…site’s environmental and process monitoring program forms part of the overall contamination control strategy” and that “the information from these systems should be used for routine batch release…..” giving clear direction that the contamination control strategy and review of the controls and monitoring of the elements contained therein should form the basis for batch disposition of sterile products. In addition to focus on the contamination control strategy the new Annex 1 provides guidance and clarification on some of the items that need to be considered as part of the batch release process and one example of this is the requirement as per the new Annex 1 to confirm the integrity of the final sterilisation gas filter on compressed gas systems used in aseptic manufacturing and in direct contact with the product or product container [7.19]. The current Annex 1 guideline does not make specific reference to the role of the QP and this has changed somewhat in the new Annex 1 where reference is made to the “Persons responsible the quality release of sterile medicine” and the additional requirement that they “should have appropriate access to manufacturing and quality information and possess adequate knowledge and experience in the manufacture of sterile dosage forms and their critical quality attributes” which comes under a new section entitled “Pharmaceutical Quality System” [3]. The title of QP is not explicitly used however due to the intention that the new Annex 1 will not be an independent EU document but will also replace PIC/S document PE009-11 “Manufacture of Sterile Medicinal Products” when it comes into effect. Ultimately the introduction of the new Annex 1 guideline will bring change and will necessitate a change of focus for QPs currently working in the industry on sterile medicinal product batch disposition. This change will place a specific emphasis on Quality Risk Management and possession of the necessary skills for engagement in the QRM process as well as a willingness to actively engage in the implementation and ongoing management of the contamination Contact our team to discuss more –  please connect with us  +353 1 846 47 42 or contactirl@pharmalex.com.

Related posts
Objectives: New EU Medical Device and In-Vitro Diagnostic Regulations
25th November 2019
PharmaLex Internal Audit Programme Management Services
14th November 2019
Technical Helpdesk Service
7th November 2019
Vendor Management
14th October 2019
Serialisation “Use and Learn” phase will end on January 31st, 2020
8th October 2019
Regulations for the Cosmetic Products Industry
25th September 2019
Search
Recent News
  • Brexit Checklist for the Pharma Industry
    26th February 2019
  • PharmaLex to plant 250 trees to celebrate its 25th anniversary
    9th December 2019
  • Our 25th Biosimilar Molecule in Our 25th Year!
    3rd December 2019
  • The shift in responsibility for determining IR35 compliance: How will it affect regulatory staffing in the UK?
    27th November 2019
  • Objectives: New EU Medical Device and In-Vitro Diagnostic Regulations
    25th November 2019
  • EMA guidance on biosimilars in the EU
    25th November 2019
  • PharmaLex Internal Audit Programme Management Services
    14th November 2019
Categories
  • All News
  • Webinars
  • Events
Archive
PharmaLex
©2019 PharmaLex GmbH. All rights reserved.

Privacy Policy

This can be specific information about signing up to the newsletter.

Pellentesque lobortis, tellus at ultrices ullamcorper, lectus tellus consectetur lectus, id consequat leo quam quis eros. Mauris pellentesque tortor a augue pellentesque ultricies. Phasellus sit amet suscipit orci, vel dapibus ligula. Maecenas at pellentesque lectus, sit amet tristique felis. Integer fringilla risus ac neque mollis, at imperdiet lacus sodales. In vehicula orci sed vulputate interdum. Nunc sagittis non nunc eget sollicitudin.

Maecenas a mattis erat. Phasellus cursus erat non nisl pulvinar ultricies. Aenean id fringilla libero. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Morbi in ultrices elit. Suspendisse egestas hendrerit est. Integer pellentesque nisl ut justo tempus, nec suscipit dolor luctus. Cras vestibulum elementum tincidunt.

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. These emails are being sent from @pharmalexcompanies.com and are not from us. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

In compliance with the Spanish Law 15/1999, of Protection of Personal Data and in accordance with regulations approved by the Spanish RD 994/1999 inform you that your data will be part of a file located in Friedrichsdorf (Germany), whose ownership belongs to Pharmalex Spain S.L.U. The purpose of these data is the insertion in a potential job selection process. Inform the user that at any time may exercise their right of access, rectification, and deletion of data through email curriculum@pharmalex.com or to this postal address Pharmalex Spain. Coso 103, 50001 Zaragoza, Spain.